Metagenomi Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $30.57M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | During market hours | $1.25M | $-0.61 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $8.66M | $-0.55 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | During market hours | $8.51M | $-0.54 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $4.13M | $-0.68 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | $11.51M | $-0.51 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 27, 2024 | Before market open | – | – | – |
Press releases
Announcements Metagenomi Therapeutics filed with the SEC
Precision gene editing designed to deliver durable, curative medicines Corporate Presentation September 2026
Regulation FD disclosure · EX-99.1 to Form 8-K
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Precision gene editing designed to deliver durable, curative medicines Hemophilia A lead program | IND 2026 Corporate Presentation May 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Pursuing cardiometabolic indications in partnership TTR AGT APOC3 Undisclosed Current indications: MGX's in vivo genome editing complements Ionis leadership in cardiometabolic space. 4 targets: two co-development and co-commercialization options. Multibillion dollar TAM.
Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Metagenomi Reports Third Quarter 2025 Financial Results and Announces Strategic Pipeline Prioritization and Leadership Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.3 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Metagenomi Reports Business Updates and Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Our Vision: Harness the power of our metagenomics platform to create curative genetic medicines for patients Programmable Genome Editing Tools Precise Human Gene Modification Curative Genetic Medicines AI-Driven Metagenomics Platform
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASCGT Annual Meeting 2025
Other events · EX-99.1 to Form 8-K
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Our Vision: Harness the power of our metagenomics platform to create curative genetic medicines for patients Programmable Genome Editing Tools Precise Human Gene Modification Curative Genetic Medicines AI-Driven Metagenomics Platform
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Our Vision: Harness the power of our metagenomics platform to create curative genetic medicines for patients Programmable Genome Editing Tools Precise Human Gene Modification Curative Genetic Medicines AI-Driven Metagenomics Platform
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
43rd Annual J.P. Morgan Healthcare Conference Nasdaq: MGX January 2025 Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
Other events · EX-99.1 to Form 8-K
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Metagenomi Announces Preclinical Data for Lead Hemophilia A Program
Other events · EX-99.1 to Form 8-K
Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Nasdaq listed (MGX) Non-Confidential Investor Overview Q2 2024 Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Nasdaq listed (MGX) Business Update Call May 1st, 2024, 5pm ET Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines
Agreement terminated · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Metagenomi Reports Business Updates and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K